The treatment of Cancer Risk Reduction & Emphysema with vitamins

Cancer Risk Reduction and Emphysema: Mitamins custom make quality formulas for the treatment of Cancer Risk Reduction & Emphysema with vitamins. A Cancer Risk Reduction & Emphysema formula will be made to suit you, using quality brand name ingredients. Mitamins produce custom made vitamin and supplement formulas to suit your individual health needs conveniently in one formula, one bottle and one dosage. For assistance, call toll free: 1-866-585-1390
Your Supplements Facts - Covers the formulas above
Supplement Facts

Specially Formulated for: Cancer Risk Reduction and Emphysema

  • Amount Per Serving
    % DV
    Vitamin A
    2500
    IU
    50%
    Vitamin C
    100
    mg
    167%
    Vitamin E
    100
    IU
    333%
    Zinc
    10
    mg
    67%
    CoQ-10
    15
    mg
    *
    Astragalus Extract
    50
    mg
    *
    Ginkgo Extract
    40
    mg
    *
  • Amount Per Serving
    % DV
    Grape Seed Extract
    50
    mg
    *
    Green Tea Extract
    50
    mg
    *
    L-Glutathione Reduced
    100
    mg
    *
    N-Acetyl L-Cysteine
    100
    mg
    *
    L-Glutamine
    50
    mg
    *
    * Daily Value (DV) not established
Name Your Supplement Bottle - Just how you like it
The current default name is: 
 
(Click in box to change)
Your Perfect Supplement - Custom-made just for you
Formulas form 35 Years of Medical Practice
Cancer Risk Reduction and Emphysema
Monthly Cost: $31.01
Serving Size:4-5
30 Days Money Back Guarantee
100% Satisfaction Guarantee

Cancer Risk Reduction and Emphysema Formulas Details

Customize Your Supplements - Check all that apply
4A Select additional condition(s) you want to address:


4B Select all the medication(s) you are taking:
Update This Formula
If your concern or medication is not listed here, use our Formulator, which covers 680 concerns and 1600 drugs, Click here!
Latest Health Related News:
Mouse Study Gives Clues to Colitis (HealthDay)
U.S. researchers say they've identified a specific immune deficiency that's the likely cause of ulcerative colitis -- at least in mice.
Cell Therapeutics, Inc. (CTI) Launches Phase III Study For Pixantrone In Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced the launch of its phase III clinical trial, known as PIX303, of pixantrone for patients with indolent non-Hodgkin's lymphoma (NHL) who have relapsed following first-line therapy. The Company has a Special Protocol Assessment (SPA) in place with the U.S. Food and Drug Administration (FDA) for PIX303.
This information concerning the support of Cancer Risk Reduction and Emphysema treatments provide basic knowledge which should always be discussed with your own health practitioner.
Any Questions, Call Us Toll Free: 1-866-585-1390
Mitamins Logo
Home  Multi-Conditions formulas  Cancer & Chemo  Cancer Risk Reduction  Cancer Risk Reduction and Emphysema
Live Chat System

manufactured In USA

  verisign          Trust E Finalmark

Custom Vitamins and Nutritional Supplements for Supporting Age-Related Cognitive Decline and Aging Treatments